Young patients with MVP-associated cerebral ischemia have a good prognosis with a low rate of recurrent events causing persistent deficits after diagnosis.
Answers are grounded in this paper and cite their sources.
Supports low risk of persistent deficits after MVP-associated ischemia; leaves open optimal long-term management in young patients.
We evaluated 32 young patients with mitral valve prolapse (MVP) as the only recognized cause of cerebral ischemia. The mean follow-up from the time of the first ischemic event was 8 years. At the time of the follow-up evaluation, 24 patients (75%) had a normal cardiac examination, and 4 had midsystolic clicks; only 1 had the characteristic click-murmur. In 75%, the first ischemic event was stroke. When MVP-associated ischemia was recognized, 44% had recurrent ischemic events. In the mean 4-year period between diagnosis of MVP-associated ischemia and follow-up, 16% had recurrent ischemic events, but none had a new persistent deficit from these events. At the time of follow-up, 63% of patients were taking platelet antiaggregants or anticoagulants. These data suggest a good prognosis for recurrent ischemic events after diagnosis of MVP-associated ischemia.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: